NRx Pharma says FDA completes first-cycle review of preservative-free ketamine ANDA - NRXP News | RalliesNRx Pharma says FDA completes first-cycle review of preservative-free ketamine ANDA
N
NRXP• FDA completes first-cycle review of ketamine ANDA
- NRx Pharmaceuticals set an Aug. 10 investor call to discuss the FDA’s completed first-cycle review of its ANDA for preservative-free ketamine.
- The update follows the company’s earlier disclosure on the review outcome, with focus on the remaining regulatory path and commercialization plans.
•
